ASCO Issues Global HPV Vaccination Guidelines for Cervical Cancer Prevention

MARCH 20, 2017
Jennifer Barrett, Assistant Editor
The American Society of Clinical Oncology (ASCO) released a clinical practice guideline on human papillomavirus (HPV) vaccination for the primary prevention of cervical cancer. The updated guidelines are designed for different regions worldwide based on varying socio-economic and structural resource settings.
 
The recommendations are divided according to 4 levels of resource settings: basic, limited, enhanced, and maximal.
 
For all environments and independent of resource settings:
  • Two doses of HPV vaccine are recommended for girls aged 9-14 years old, with an interval of at least 6 months and up to 12-15 months between doses.
  • Girls who have HIV should receive 3 doses.
For maximal and enhanced resource settings:
  • If girls are 15 years or older and have received their first dose before age 15, they may complete the 2-dose series.
  • If they have no received first dose before age 15, they should receive 3 doses.
  • In both scenarios, vaccination may be given through age 26 years old.
For limited and basic resource settings: 
  • If sufficient resources remain after vaccinating girls aged 9-14 years old, girls who received 1 dose may receive additional doses between ages 15-16 years old. 
For vaccination of boys in all settings, boys may be vaccinated if there is at least 50% coverage in the priority female target population, sufficient resources, and such vaccination is cost-effective.
 
The guidelines were developed by a multinational and multidisciplinary panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts.
 
Reference
 
Arrossi S, Temin S, Garland S, et al. Primary prevention of cervical cancer. ASCO. Mar. 17, 2017. doi: 10.1200/JGO.2016.008151.
 
First Global Guidance for HPV Vaccination for Cervical Cancer Prevention [news release]. Virginia. ASCO’s website. http://www.asco.org/about-asco/press-center/news-releases/first-global-guidance-hpv-vaccination-cervical-cancer. Accessed Mar. 20, 2017. 
 

SHARE THIS SHARE THIS
1

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.